NCT02494700View on ClinicalTrials.gov

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 6, 2015

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Ann Arbor Stage I B-Cell Non-Hodgkin LymphomaAnn Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage I Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage I Mantle Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin LymphomaAnn Arbor Stage II Grade 1 Follicular LymphomaAnn Arbor Stage II Grade 2 Follicular LymphomaAnn Arbor Stage II Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage III Mantle Cell LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage IV Mantle Cell LymphomaOcular Adnexal LymphomaOcular Adnexal Mucosa-Associated Lymphoid Tissue LymphomaOrbit Lymphoma
Interventions
RADIATION

External Beam Radiation Therapy

Undergo orbital EBRT

DRUG

Orbital Radiation

Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER